Protein and mRNA Expression Levels of Interleukin-17A, -17F and -22 in Blood and Skin Samples of Patients with Mycosis Fungoides

Despoina PAPATHEMELI1, Aikaterini PATSAISI1, Dimitrios PAPANASTASSIOU2, Triantafyllia KOLETSAA, Thomas PAPATHEMELIS6, Chrysostomos AVGEROSS, Olga PIKOU4, Elizabeth LAZARIDOUD and Elisavet GEORGIOU5

1Second Department of Dermatology and Venereology, Cutaneous Lymphoma Outpatient Clinic, 2Department of Pathology and 5Laboratory of Biomedical Chemistry, Faculty of Medicine, Aristotle University of Thessaloniki, 3Department of Applied Informatics, University of Macedonia, Thessaloniki, Greece and 4Department of Gynecology and Obstetrics, Klinikum St. Marien Amberg, Amberg, Germany

This study investigated the expression of interleukin (IL)-17A, -17F and -22 in mycosis fungoides. Blood samples were collected from 50 patients with mycosis fungoides and 50 healthy controls. Skin samples were obtained from 26 patients with mycosis fungoides and 5 healthy controls. Protein levels of IL-17A, -17F and -22 were measured in serum by multiplex enzyme-linked immunosorbent assay, and mRNA expression levels were measured in blood and skin samples by real-time quantitative reverse transcription PCR. Both IL-17A and IL-17F mRNA expression levels were significantly lower in blood of patients with mycosis fungoides in comparison with healthy controls. IL-22 serum levels and expression levels of IL-22 mRNA in skin tissue, were significantly increased in patients with mycosis fungoides in comparison with healthy controls. These results suggest that low levels of IL-17A and IL-17F in mycosis fungoides may be connected to impaired immune surveillance contributing to tumourigenesis. Upregulation of IL-22 may play a role in the establishment of the tumour microenvironment in mycosis fungoides.

Key words: mycosis fungoides; primary cutaneous T-cell lymphoma; CTCL; IL-17A; IL-17F; IL-22.

Accepted Nov 4, 2020; Epub ahead of print Nov 10, 2020
Acta Derm Venereol 2020; 100: adv00326.
Corr: Despoina Papathemeli, Papageorgiou General Hospital, GR-56403 Efkarpia, Greece. E-mail: dpapathem@live.com

Mycosis fungoides (MF), with an incidence of 0.4–0.5/100,000 people per year, is the most common type of primary cutaneous T-cell lymphoma (CTCL) (1). In early stages the disease presents clinically with limited patches or plaques in a bathing suit distribution (lower trunk, buttocks, groin, axillae, breasts). Early-stage MF is characterized by an uneventful disease course and a favourable prognosis; nevertheless early-stage MF can progress to advanced disease in 25% of cases (2). In advanced stages of MF patients may develop skin tumours or erythroderma, lymph node or visceral spread, and blood involvement, resulting in a poor prognosis (3).

The exact pathogenetic mechanism and the cytokine interplay that occurs in the MF microenvironment is unknown. In early-stage MF, the skin shows a Th1 cytokine pattern characterized by normal-to-increased expression of interferon (IFN)-γ, interleukin (IL)-2 and IL-12, whereas in late-stage MF, there is a loss of Th1 cytokines and an increase in Th2 cytokines (IL-4, IL-5, IL-10 and IL-13). This could be partially explained by the predominance of CD8+ T cells in early stages of the disease, which exhibit a Th1 phenotype and contribute to an anti-tumour response, while in advanced stages the increased number of malignant CD4+ T cells leads to Th2 skewing (4). However, little is known about the role of Th17 and Th22 and their related cytokines in MF.

Th17 cells are a distinct class of T-helper lymphocytes, which play a role in the immune defence, fighting pathogens that cannot be managed by Th1 and Th2. Th17 cells produce IL-17A, IL-17F as well as IL-21, IL-22 and granulocyte-macrophage colony-stimulating factor (GM-CSF) (5). The Th17 lineage is implicated in a number of autoimmune disorders, including psoriasis, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease (5, 6). Th22 is a relatively new class of CD4+ T cells with specific characteristics: they produce IL-22, IL-13 and tumour necrosis factor (TNF)-α, but not IL-17 or IFN-γ (7, 8). Th22 cells affect mesenchymal and epithelial cells and play a role in inflammatory skin conditions, such as atopic dermatitis (6).

Both Th17 and Th22 play an important role in the skin. Irritated epithelial keratinocytes produce IL-1β and IL-6 and stimulate intraepidermal Langerhans cells and dermis-resident dendritic cells to produce IL-23 and migrate to lymph nodes, where Th17 and Th22 differentiate respectively to the antigens presented to them by the antigen-presenting cells (APCs) and migrate to sites of inflammation in the skin. Skin-homing Th17 and Th22 produce IL-17A, IL-17F, IL-22 and TNF-α, which in turn affect mesenchymal and epithelial cells and play a role in inflammatory skin conditions, such as atopic dermatitis (6).
activate keratinocytes to produce cytokines (IL-32 and IL-36), chemokines (CXCL1 and CCL20) and antimicrobial peptides (HBD-2 and S100A7/psoriasin and S100A15/koebernerisin) that induce local inflammatory reactions (9, 10).

Apart from Th cells, another cellular source of IL-17A, IL-17F and IL-22 are type 3 innate lymphoid cells (ILC3), which are part of the innate immune system. Both IL-17A/F and IL-22 can be produced by ILC3 simultaneously or separately (11). Recent experimental studies indicate the presence of ILC3 in psoriatic skin (12–14). However, their function in the cutaneous immune network is ill-defined and relatively unexplored.

The role of Th17 producing IL-17A, IL-17F and IL-22 in the pathogenesis of psoriasis is well known (15). In the psoriatic skin, IL-22 is also produced by Th22 cells and increased production of IL-22 receptor is observed (16, 17). In line with Th cells, ILC3 are also accumulated in peripheral blood, lesional and non-lesional skin of patients with psoriasis (12–14). Patients with psoriasis are at increased risk of developing CTCL (18, 19). Assuming that this may be caused by a common pathogenetic pathway, it was considered that it would be of great scientific interest to investigate the expression of IL-17A, IL-17F and IL-22 in patients with MF.

MATERIALS AND METHODS

Peripheral blood and skin tissue samples
Peripheral blood samples were obtained from 50 patients with MF and 50 healthy controls. Skin tissue samples were obtained from 26 patients with MF and 5 healthy controls. Samples were collected from newly diagnosed patients with MF and from patients with a previous history of MF with active disease despite treatment. Patients with a history of MF, but in full remission, were excluded. Healthy controls had no history of autoimmune or malignant disease. Samples were collected during daily clinical practice in our facilities. Informed consent was obtained from all patients and healthy controls. The study was approved by the bioethics committee of Aristotle University of Thessaloniki, Greece, and was conducted according to the principles of the Declaration of Helsinki.

Enzyme-linked immunosorbent assay
IL-17A, IL-17F and IL-22 protein levels in sera were measured using Milliplex® MAP technology. Th17 Magnetic Bead Panel kit was obtained from Merck, Millipore, USA, and the procedure was performed according to the manufacturer’s instructions. Results were acquired by Luminex® xPONENT® acquisition software using Luminex® 200™ System (Luminex Corporation, Austin, Texas, USA).

Real-time quantitative reverse transcription PCR assay
The mRNA expression levels in blood and skin tissue were measured with real-time quantitative reverse transcription PCR (RT-qPCR). RNA isolation was performed using Nucleospin RNA kit (Macherey-Nagel GmbH & Co. KG, Düren, Germany). cDNA was synthesized from 500 ng total RNA, using PrimeScript 1st strand cDNA synthesis kit (TaKaRa Bio Inc, Japan). RT-qPCR was performed in the StepOnePlus™ Real-Time PCR System (Applied Biosystems) using SybrGreen-based technology (2x qPCR BIO SyGreen Mix Hi-ROX, PCR BIOSYSTEMS, UK) and the following primers: IL-17A: forward 5’-AACCTGAACATCCAATCCTCAGACATCAGC3’, reverse 5’-GTGGCACAGGAGTGATTATGAACGC3’; IL-17F: forward 5’-GTGACCAGGAGTGATTATGAACGC3’ and reverse 5’-ATGCTCTTCTTCTCCTGACATT3’, IL-22: forward 5’-ATGCTGTGTTCTCCTGACATC3’ and reverse 5’-CTTCAGCTTGTTGCCG3’ (product size 139bp, 200bp and 149bp, respectively). GAPDH was used as a reference gene and amplified using primers: forward 5’-AGCCACATCGCTCAAGACACC3’ and reverse 5’-GGCGCCAATAGCAGCAAAATC3’ (product size 67 bp). Cycling conditions included an initial polymerase activation cycle at 95°C for 2 min, followed by 40 cycles of denaturation at 95°C for 5 s, and anneal/extension at 60°C for 20 s. The specificity of the products was assessed by melting curve analysis and/or agarose gel electrophoresis. The relative quantity of mRNA expression was calculated by the 2^(-ΔΔCt) method (20).

Statistical analysis
To investigate differences in mean values for the protein/mRNA levels of the interleukins of interest between patients and controls, statistical tests were applied to reject the null hypothesis of equality. Because of the skewed nature of the current data, parametric tests were performed assuming that the logarithmically transformed observations follow a normal distribution. For the mRNA expression levels, where all observations were recorded as numerical values, the p-values of a 2-sided t-test were calculated, using the Welch approximation. Regarding the enzyme-linked immunosorbent assay (ELISA) concentration data, where the current data contained a considerable percentage of cases in which the record was that there was a lower than laboratory detection limit value, a parametric log-normal likelihood ratio test for left-censored data was applied, which is the reciprocal of the above usual t-test. Software to implement the latter method is available through the free statistical language R, from the NADA and EnvStats packages (21). A valuable guide to the methods is provided in documentation from USEPA and R packages (22, 23). To validate the current results, exploratory work examined that the log-normal model assumption was fulfilled satisfactorily and the findings were compared with alternative procedures.

RESULTS

Demographic and clinical characteristics of patients recruited in this study
A total of 50 patients with MF were recruited (n=50, median age 60.6 years). Among them 34 were male and 16 female, 16 cases had patch-stage disease, 23 cases had plaques, 6 cases tumours, and 5 patients were erythrodermic. Furthermore, the current sample comprised 39 patients with early-stage MF (Ia–Iia) and 11 patients with advanced-stage MF (Iib–IV). All patients had LDH serum levels within normal reference range. Twenty-two patients had not received any treatment prior to sample collection. The remaining patients had received skin-directed or systematic treatment, or a combination of those, depending on the disease status. Skin samples from punch/incisional biopsies were collected from 26 consenting patients undergoing biopsy for diagnostic/re-evaluation purposes and were included in the study after histological
Expression of IL-17A, IL-17F and IL-22 in patients with MF

There was no statistically significant difference between serum levels of IL-17A and IL-17F, measured by ELISA, between patients and healthy controls (p = 0.0720 and p = 0.6600, respectively). However, serum levels of IL-22 in patients were significantly higher than in healthy controls (p = 0.0076) (Fig. 1 and Table II). No statistically significant difference in IL-17A, IL-17F and IL-22 serum levels in patients was found between males and females, between early- and advanced-stage patients and between patients at different clinical stages (patch, plaque, tumour, erythroderma). Patients who had received skin-directed therapy had higher levels of IL-17F in comparison with patients under systemic treatment, under combination treatment and under no treatment at all (p = 0.0250). However due to the small sample size (only 3 patients received skin-directed therapy), this result is very doubtful.

Expression levels of interleukin-17A, -17F and -22 mRNA in blood samples measured by RT-qPCR

IL-17A and IL-17F mRNA expression levels were significantly lower in the blood samples from patients in comparison with healthy controls (p = 0.0089 and p = 0.0004, respectively). There was no statistically significant difference in IL-22 mRNA expression in blood between patients and healthy controls (p = 0.7308) (Table III and Fig. 2). No statistically significant difference in IL-17A, IL-17F and IL-22 mRNA expression levels in blood samples from patients was found between males and females, between early- and advanced-stage patients, between patients with different clinical stages (patch, plaque, tumour, erythroderma) and between patients under different treatment regimens (skin-directed therapy, systemic therapy, both skin-directed and systemic therapy and no therapy at all).

Expression levels of interleukin-17A, -17F and -22 mRNA in skin tissue samples measured by RT-qPCR

There was no statistically significant difference in IL-17A and IL-17F mRNA expression levels in skin tissue samples, measured by RT-qPCR, between patients and controls (p = 0.3641 and p = 0.6925, respectively). However, expression levels of IL-22 mRNA in skin tissue were increased in samples from patients with MF in comparison with healthy controls (p = 0.0319) (Table IV and Fig. 3). No statistically significant difference in IL-17A, IL-17F and IL-22 mRNA expression levels in skin tissue from patients was found between males and females, between early- and advanced-stage patients, between patients with different clinical stages (patch,
plaque, tumour, erythroderma), or between patients under different treatment regimens.

**DISCUSSION**

The exact role of Th17, Th22, ILC3 and the associated cytokines in the immune dysfunction observed in MF have not yet been fully elucidated. IL-17A and IL-17F mRNA expression levels in blood samples in this study were significantly lower in patients with MF, in comparison with healthy controls. Furthermore, elevated IL-22 protein levels were detected in the serum of patients, as well as elevated IL-22 mRNA expression in skin tissue samples of patients, in comparison with healthy controls. These data suggest that MF unbalanced immunity may be characterized by downregulation of IL-17A and IL-17F and upregulation of IL-22.

There are very few studies of the concentration of IL-17A, IL-17F and IL-22 in blood or skin samples of patients with MF, and these studies often present conflicting results. The current findings are consistent with those from a study from Miyagaki et al. (24) in 2011, who demonstrated that IL-22, but not IL-17A and IL-17F, were significantly elevated in lesional skin of CTCL. In the same study, serum IL-22 levels were increased in patients with CTCL and correlated with disease severity. In the current study, however, neither IL-22 levels in serum nor IL-22 mRNA expression in blood and lesional skin tissue correlated with disease severity. In 2013 a case of Sézary syndrome was reported, characterized by high levels of circulating IL-22-producing CD8+ tumour cells under a condition of bacterial sepsis (25). The lack of IL-17 in lesional skin of CTCL has been observed in a study by Wolk et al. (26), in which it was demonstrated that the increased skin infection risk in patients with MF is associated with impaired upregulation of antibacterial proteins (ABPs), and that IL-17A and IL-17F deficiency may be responsible for this. Furthermore, in a study from Circé et al. (27) in 2004, 5 out of 10 MF/SS biopsies expressed IL-17 mRNA, whereas this cytokine was absent in normal skin. IL-17 mRNA was not detected in the biopsies from 2 patients with initially localized MF, whereas upregulation of IL-17 was demonstrated during disease progression. Similarly, Krejsgaard et al. (28) found that, IL-17A and IL-17F mRNA expression was significantly increased in CTCL skin lesions compared with healthy donors and patients with chronic dermatitis, but patients with MF displayed a considerable heterogeneity in IL-17A and IL-17F expression, and the level of expression was higher in advanced-stage disease. Furthermore, IL-17F expression was associated with progressive disease. In a previous study by the same group in 2011, IL-17 protein was detected by immuno­histochemistry in 10 out of 13 examined skin lesions, but not in the sera from 28 patients with CTCL, using ELISA (29). In another study Chong et al. (30) detected by qPCR elevated IL-17 levels in stimulated peripheral blood mononuclear cells (PBMCs) from early MF/CTCL and late MF/CTCL without blood involvement (−B) compared with PBMCs from normal, psoriasis and MF/CTCL with blood involvement (+B). PBMCs from late MF/CTCL with blood involvement (+B) had the lowest levels of IL-17 of all groups.

Studies that have attempted to characterize IL-17A, IL-17F and IL-22 involvement in MF have various results. This could be interpreted by differences between research groups in the study population and controls, in the samples included (skin biopsies, PBMCs, peripheral blood) and the different methodologies and techniques used (ELISA, immunohistochemistry, mRNA expression). A major weakness of the above studies is that they all have small sample sizes due to the rarity of the disease.

![Fig. 2. mRNA expression of interleukin (IL) - 17A, IL-17F and IL-22 in blood samples from patients vs controls. *: Sample mean. RQ: relative quantity.](image-url)
The low levels of IL-17A and IL-17F mRNA expression in blood in the current study might reflect the defective host anti-tumour immune response. Th17 cells and their innate equivalent natural cytotoxicity receptor– (NCR–) ILC3 cells produce IL-17, which possesses both pro-tumourigenic and anti-tumourigenic functions (11, 31). Moreover, Murray et al. (32) have demonstrated that IL-17 is produced, not only, by malignant T-cells, but also by non-malignant tumour-infiltrating lymphocytes (TILs) in MF, and that expression of IL-17 decreases during disease progression. The high production of IL-17 from TILs reflects the role of IL-17 in host anti-tumour immunity. IL-17A and IL-17F might play a crucial role in immune surveillance and a decrease in these cytokines may lead to disease progression. This hypothesis is reinforced by reports of psoriatic patients who developed MF after short-term treatment with the IL-17A antibodies secukinumab and ixekizumab (33–35).

The current findings of elevated IL-22 protein levels in serum and IL-22 mRNA expression in skin tissue raise questions about the possible role of IL-22 in the pathogenesis of MF. IL-22 is involved in the modulation of tissue responses during inflammation and plays a role in many inflammatory skin conditions, such as atopic dermatitis and psoriasis (16). IL-22 is also important for maintaining epithelial integrity and for protection against pathogens (36, 37), thus exerting an anti-tumour role. Although Th17 and Th22 are the foremost source of IL-22, recently published data have shown that this cytokine is also produced in the skin by NKp44+ (NCR+) ILC3 cells. ILC3 cells have a dual role in tumourigenesis. They present an anti-tumour effect by releasing TNF and promoting leucocyte recruitment and they also increase tumour growth and tumour cell mobility through IL-22 secretion and STAT3 signalling (38). IL-22 mRNA levels in tissue samples in the current study were not correlated with disease stage, thus we cannot draw conclusions about the prominent role of IL-22 in the development and evolution of MF. Adding to complexity, IL-22 effect can be neutralized by IL-22-binding protein (IL-22BP), which binds free IL-22 (37). Dysregulation of IL-22 expression and signalling has been observed in many common cancers, such as colon, lung and liver cancer. IL-22 receptor is expressed on epithelial cells of the skin, the gastrointestinal tract and the respiratory tract, but not on immune cells. This restricted tissue specificity makes IL-22 a promising future therapeutic target, probably with fewer side-effects (39). Further research is needed to evaluate the potential therapeutic benefit of targeting IL-22 in MF.

**Study limitations**

A limitation of this study is the small sample size, which might explain the fact that IL-17A and IL-17F downregulation in patients with MF was detected only by mRNA expression level in the blood, and not by protein level in serum or mRNA expression level in skin tissue. Similarly, IL-22 showed significant upregulation in mRNA expression level in skin tissue and in protein level in the serum of patients in comparison with healthy controls, but not in mRNA expression in the blood. Another reason for this discrepancy is that concentration levels of these cytokines, especially in the blood, are very low and cannot easily be detected. In the current study many concentration values in the ELISA were below the detection limit, and survival analysis statistical methods for left-censored data had to be used to overcome this limitation. A further limitation of the current study is the lack of functional data on possible molecular and cellular mechanisms that would explain these immune dysregulations, which would further support the current findings.

**Conclusion**

The results of this study suggest that the MF tumour microenvironment is characterized by downregulation of IL-17A and IL-17F and upregulation of IL-22. At present it is not known whether these cytokine expression abnormalities are directly responsible for the pathogenesis of the disease, are signs of an ineffective host immune response, or are epiphenomena to the underlying neoplastic mechanisms (40). However, by understanding how cytokine signalling in the tumour microenvironment influences malignant T cells, it might be possible to develop new targeted therapies in the future (41). Additional multi-centre studies including a larger number of patients are needed to further elucidate the cytokine imbalances and immune dysregulation that occur in MF.

**ACKNOWLEDGEMENT**

This study was funded by the General Secretariat for Research and Technology (GSRT) of Greece and the Hellenic Foundation for Research and Innovation (HFRI).
The authors have no conflicts of interest to declare.

REFERENCES

1. Teras LR, Desantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016; 66: 443–459.

2. Haun PL, Scarisbrick JJ. Fast facts: cutaneous T-cell lymphoma. 1st edn. Oxford: S. Karger Publishers Ltd, 2019: p. 1–57, 81–105.

3. Scarisbrick JJ, Quaglino P, Prince HM, Papadavides E, Hodak E, Bagot M, et al. The PROCLIP international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol 2019: 181: 350–357.

4. Wong HK, Mishra A, Hake T, Porcu P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). Br J Haematol 2011; 155: 150–166.

5. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages key words. Annu Rev Immunol 2007; 25: 821–852.

6. Ivanova EA, Orekhov AN. T helper lymphocyte subsets and plasticity in autoimmunity and cancer: an overview. Biomed Res Int 2015: 2015: 32747.

7. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH17, TH1 and TH2 cells. Nat Publ Gr 2009; 10: 864–871.

8. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Publ Gr 2009; 10: 857–863.

9. Kabashima K. Immunology of the skin. Basic and clinical sciences in skin immune responses. Springer; Japan 2016; p. 463–471.

10. Weaver CT, Elson CO, Fouser LA, Kolls JK. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu Rev Pathol Mech Dis 2013; 8: 477–512.

11. Mjösberg J, Eidsmo L. Update on innate lymphoid cells in skin and blood of psoriasis patients. J Invest Dermatol 2014; 138: 2351–2360.

12. Dyring Andersen B, Geisler C, Agerbeck C, Lauritsen JPH, Gúdjonsdottir SD, Skov L, et al. Increased number and frequency of group 3 innate lymphoid cells in nonlesional skin and blood demonstrates increase of NKp44+ ILC3 in cutaneous T-cell lymphoma. Br J Dermatol 2014; 170: 609–616.

13. Villanueva F,Flutter B,Tosi I,Grys K,Sreeenebus H,Perera GK, et al. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ILC3 in psoriasis. J Invest Dermatol 2014; 134: 984–991.

14. Te Velde A, et al. Composition of innate lymphoid cell subsets in the human skin: Enrichment of NCR + ILC3 in lesional skin and blood of psoriasis patients. J Invest Dermatol 2014; 134: 2351–2360.

15. Boehncke WH, Schön MP. Psoriasis. Lancet 2015; 352: 1899–1912.

16. Fujita H. The role of IL-22 and Th22 cells in human skin diseases. J Dermatol Sci 2013; 72: 3–8.

17. Tohyama M, Yang L, Hanakawa Y, Dai X, Shirakata Y, Sayama K. IFN-α enhances IL-22 receptor expression in keratinocytes and is essential in the development of psoriasis. J Invest Dermatol 2012; 132: 1933–1935.

18. Donigan J, Snowden C, Carter J, Kimball A. The temporal association between cutaneous T-cell lymphoma and psoriasis: implications for common biologic processes. J Eur Acad Dermatol Venereol 2015; 30: e31–32.

19. Papathemeli D, Georgiou E, Koletsa T, Sotiriadis D, Patsatsi A. Mycosis fungoides in patients with psoriasis: an ongoing issue. Eur J Dermatol 2018; 28: 235–236.

20. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008; 3: 1101–1108.

21. R Core Team. R: A Language and environment for statistical computing. Vienna: R Foundation for Statistical Computing 2020. Available from: https://www.r-project.org/.

22. USEPA. Statistical analysis of groundwater monitoring data at RCRA facilities, unified guidance. EPA 530/R-09-007, March 2009. Office of Resource Conservation and Recovery Program Implementation and Information Division. Washington, DC: US Environmental Protection Agency, 2009: Ch 15.

23. USEPA. Errata sheet – March 2009 unified guidance. EPA 530/R-09-007a, August 9, 2010. Office of Resource Conservation and Recovery, Program Information and Implementation Division. Washington, DC: US Environmental Protection Agency, 2010.

24. Miyagaki T, Sugaya M, Suga H, Kamata M, Ohmatsu H, Fujita H, et al. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma. Clin Cancer Res 2011; 17: 7529–7538.

25. Shimauchi T, Sasada K, Kito Y, Mori T, Hata M, Fujiyama T, et al. CD84+ Sézary syndrome with interleukin-22 production modulated by bacterial sepsis. Br J Dermatol 2013; 168: 881–883.

26. Wolk M, Mitsui H, Witte K, Gelrich S, Gulati N, Humme D, et al. Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: role of Th2-mediated biased Th17 function. Clin Cancer Res 2014; 20: 5507–5516.

27. Cirée A, Michel L, Camilleri-Broët S, Louis FJ, Oster M, Flageul B, et al. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sézary syndrome). Int J Cancer 2004; 111: 123–130.

28. Krejsgaard T, Litvinov I V, Wang Y, Xia L, Willerslev-Olsen A, Korolov SB, et al. Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma. Blood 2013; 122: 943–950.

29. Krejsgaard T, Ralfkiaer U, Clasen-Linde E, Eriksen KW, Kopp KL, Bonefeld CM, et al. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. J Invest Dermatol 2011; 131: 1331–1338.

30. Chong BF, Wilson AJ, Gibson HM, Hafner MS, Luo Y, Hedgcock CJ, et al. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides. Clin Cancer Res 2008; 14: 646–653.

31. Zou W, Restifo NP. TH17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010; 10: 248–256.

32. Murray D, McMurray JL, Eldershaw S, Pearce H, Davies N, Scarisbrick JJ, et al. Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR. Blood Adv 2019; 3: 519–530.

33. Yoo J, Shah F, Velangi S, Stewart G, Scarisbrick JS. Secukinumab for treatment of psoriasis: does secukinumab precipitate or promote the presentation of cutaneous T-cell lymphoma? Clin Exp Dermatol 2012; 37: 414–417.

34. Yoo J, Shah F, Velangi S, Stewart G, Hague J, Scarisbrick J. Three cases of new diagnosis of mycosis fungoides following commencement on biologic therapies for presumed psoriasis/eczema. Eur J Cancer 2019; 119: S41.

35. Amitay-Laish I, Aklivov OE, Guenova E, Ortiz Romero PL, Rozati S, Vico-Alonso C, et al. Blocking TNF-α/Th17 pathway with monoclonal cytokine antibodies may aggravate the course of mycosis fungoides: a multicenter retrospective analysis of real-world clinical data. Eur J Cancer 2019; 119: S42.

36. Kim BS. Innate lymphoid cells in the skin. J Invest Dermatol 2015; 135: 673–638.

37. Hernandez P, Gronke K, Diefenbach A. A catch-22: Interleukin-22 and cancer. Eur J Immunol 2018; 48: 15–31.

38. Chiossone L, Dumas PY, Viennie M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol 2018; 18: 671–688.

39. Lim C, Savan R. The role of the IL-22/IL-22R1 axis in cancer. Cytokine Growth Factor Rev 2014; 25: 257–271.

40. Willerslev-Olsen A, Litvinov I V, Fredholm SM, Petersen DL, Sibbesen NA, Gniadecki R, et al. IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF). Cell Cycle 2014; 13: 1306–1312.

41. Abraham RM, Zhang Q, Oudum N, Wasik MA. The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma. Cancer Biol Ther 2011; 12: 1019–1022.